"Designing Growth Strategies is in our DNA"

Atopic Dermatitis Treatment Market Size, Share And Global Trend By Drug Class (Corticosteroids, Anti-histamines, Calcineurin inhibitors, Interleukin inhibitors, Topical phosphodiesterase-4, Antibiotics, Others), By Route of Administration (Oral, Topical, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Regional Forecast, 2024-2032

Region : Global | Report ID: FBI100579 | Status : Ongoing

 

KEY MARKET INSIGHTS

In March 2019, Regeneron Pharmaceuticals, Inc. and Sanofi received approval for Dupixent for the treatment of Atopic Dermatitis in adolescent patients. Atopic dermatitis also referred to as Eczema, is a severe skin condition resulting in dry and itchy skin. In atopic dermatitis, dry and red patches appear on the scalp, cheeks, forehead, and face. Estimates for the prevalence of atopic dermatitis varies. Atopic dermatitis is most common in infants especially in the first year after birth. According to the British Association of Dermatologists, one in every 5 children in the United Kingdom is affected by eczema at some stage.  According to the estimates of the National Institute for Health and Care Excellence, atopic dermatitis affects 1 in every 12 adults in the United Kingdom.


The growth in global atopic dermatitis treatment market is estimated to be driven by the increase in the prevalence of atopic dermatitis and advancements in atopic dermatitis treatment. According to the Asthma and Allergy Foundation of America, approximately 7.3% of individuals suffered from atopic dermatitis in the U.S in the year 2016. Apart from these, the recent key mergers and acquisitions with respect to atopic dermatitis are also expected to fuel the global atopic dermatitis treatment market.

To gain extensive insights into the market, Request for Customization


The factor that is projected to restrain the global atopic dermatitis treatment market is the non-curable nature of the disease. Additionally, the stringent regulatory guidelines combined with the introduction of generic treatment methods are anticipated to negatively affect the global atopic dermatitis treatment market.

Key Players Covered


Some of the major companies that are present in the global atopic dermatitis treatment market are Novartis AG, Pfizer Inc., Astellas Phrama Inc., Meda, Bayer AG, Allergan, Regeneron Pharmaceuticals, Inc., and other players.

SEGMENTATION


























SEGMENTATION


 DETAILS


By Drug Class


·      Corticosteroids

·      Anti-histamines

·      Calcineurin inhibitors

·      Interleukin inhibitors

·      Topical phosphodiesterase-4

·      Antibiotics

·      Others


By Route of Administration


·      Oral

·      Topical

·      Injectable


By Distribution Channel


·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies


By Geography


·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


                       

Corticosteroids are anticipated to register higher share in the segmentation by drug class of global atopic dermatitis market as it is the first line of treatment for the disease.

Key Insights


Overview of the prevalence of atopic dermatitis in key countries

Pipeline analysis

Porter’s five forces analysis

Key mergers and acquisitions

Regional Analysis


The global atopic dermatitis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is anticipated to dominate the global atopic dermatitis market followed by Europe owing to the wider healthcare access and evolved healthcare infrastructure. The global atopic dermatitis treatment market is anticipated to grow in Europe owing to the increase in the prevalence of atopic dermatitis. According to the National Institute for Health and Care Excellence, from 2014 to 2015, there were 895 admissions in England for atopic dermatitis. In the emerging countries of Asia Pacific, the global atopic dermatitis market is projected to grow at a higher CAGR in the forecast period owing to the increasing awareness of atopic dermatitis among the patient pool.

Key Industry Developments



  • In 2016, Pfizer Inc. acquired Anacor Pharmaceuticals, Inc., which will strengthen its presence in the dermatology market as well as in global atopic dermatitis treatment market.

  • In 2018, Galapagos NV and MorphoSys AG entered into a worldwide agreement with Novartis AG for MOR106, a monoclonal antibody being developed for the treatment of atopic dermatitis.

  • In the fiscal year of 2016, Eucrisa developed by Pfizer Inc. was approved by the U.S FDA for the treatment of atopic dermatitis


  • Ongoing
  • 2023
  • 2019-2022

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $6850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

abbvie
Siemens Healthineers
iqvia
Jubilant
Roche

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X